Innoviva (INVA) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Innoviva (INVA) over the past year, gaining 153.4% versus a loss of 12.2%. Innoviva is the larger company by market cap ($1.31 billion vs $1.26 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | LBRX |
|---|---|---|
| Share price | $18.41 | $38.85 |
| Market cap | $1.31B | $1.26B |
| 1-day change | 0.00% | -2.97% |
| YTD return | -7.90% | +74.53% |
| 1-year return | -12.17% | +153.42% |
| 5-year return | +8.81% | — |
| P/E ratio (TTM) | 7.83 | — |
| Forward P/E | 8.33 | — |
| EPS (TTM) | $2.35 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $411.33M | — |
| Revenue growth (YoY) | +14.67% | — |
| Net income (latest FY) | $271.17M | $-25.20M |
| Gross margin | 74.80% | — |
| Operating margin | 39.81% | — |
| Net margin | 65.92% | — |
| 52-week high | $25.15 | $50.16 |
| 52-week low | $18.19 | $15.55 |
| Distance from 52-week high | -26.80% | -22.55% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +89.03% | +49.29% |
| Average volume | 865.66K | 373.16K |
| Shares outstanding | 71.08M | 32.36M |
| Employees | 159 | 62 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed INVA by 165.6 percentage points over the past year.
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees
INVA vs LBRX FAQ
Which is bigger, Innoviva or LB Pharmaceuticals?
Innoviva (INVA) is larger, with a market capitalization of $1.31B compared with $1.26B for LB Pharmaceuticals (LBRX).
Which stock has performed better over the past year, INVA or LBRX?
LBRX returned +153.42% over the past 12 months, compared with -12.17% for INVA (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.